Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial

Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial

Background: Dupuytren's disease is a common fibrotic condition of the hand that causes irreversible flexion contractures of the fingers, with no approved therapy for early stage disease. Our previous analysis of surgically-excised tissue defined tumour necrosis factor (TNF) as a potential thera...

Full description

Bibliographic Details
Main Authors: Jagdeep Nanchahal, Catherine Ball, Dominique Davidson, Lynn Williams, William Sones, Fiona E. McCann, Marisa Cabrita, Jennifer Swettenham, Neil J. Cahoon, Bethan Copsey, E. Anne Francis, Peter C. Taylor, Joanna Black, Vicki S. Barber, Susan Dutton, Marc Feldmann, Sarah E. Lamb
Format: Article
Language:English
Published: Elsevier 2018-07-01
Series:EBioMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396418302299

Internet

http://www.sciencedirect.com/science/article/pii/S2352396418302299

Similar Items